Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor 5-year
survival rates, necessitating identification of novel therapeutic targets. Elucidating the …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer that typically
demonstrates resistance to chemotherapy. Tumor-associated macrophages (TAMs) are …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, characterized
by a treatment-resistant and invasive nature. In line with these inherent aggressive …

Within a tumor, cancer cells exist in different states that are associated with distinct tumor
functions, including proliferation, differentiation, invasion, metastasis, and resistance to anti …

Background & Aims As pancreatic ductal adenocarcinoma (PDAC) continues to be
recalcitrant to therapeutic interventions, including poor response to immunotherapy, albeit …

Large-scale genomic profiling of pancreatic cancer (PDAC) has revealed two distinct
subtypes:'classical'and 'basal-like'. Their variable coexistence within the stromal immune …

Background The molecular mechanisms underlying innate tumor drug resistance, a major
obstacle to successful cancer therapy, remain poorly understood. In colorectal cancer …

Background Pancreatic ductal adenocarcinoma (PDAC) is most aggressive among all
gastrointestinal tumors. The complex intra-tumor heterogeneity and special tumor …

Purpose: Early detection of pancreatic ductal adenocarcinoma (PDAC) remains elusive.
Precursor lesions of PDAC, specifically intraductal papillary mucinous neoplasms (IPMNs) …

Pancreatic ductal adenocarcinoma (PDA) is a heterogeneous disease comprised of a basal-
like subtype with mesenchymal gene signatures, undifferentiated histopathology and worse …